SCHEMBL6645761

SCHEMBL6645761

Cc1ccc(C(=O)Nc2ccc3c(c2)CCN3C(=O)CCl)c(OC(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.50
▸ TP53 P04637 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ LMNA P02545 2/20 0.44
▸ POLB P06746 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ CASP2 P42575 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645986 0.88 SMN1; SMN2 (0.65) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6643701 0.84 MAPT (0.49) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6648070 0.84 SMN1; SMN2 (0.44) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6646954 0.84 MAPT (0.44) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6645715 0.82 MAPT (0.42) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6646347 0.82 MAPT (0.42) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6645215 0.80 MAPT (0.40) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6643740 0.78 MAPT (0.39) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6643745 0.78 MAPT (0.39) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6645467 0.76 HTR2C (0.51) MAPTLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 — — US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR MAPT 4101/4885TP53 4513/4885SMN1; SMN2 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback